CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
Keler Marku joins CRA's Antitrust & Competition Practice
“We are pleased to welcome Keler back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Keler is an expert in...